CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer ...
The trial in progress poster titled “ A phase 1 trial of pretargeted radioimmunotherapy with GD2-SADA: 177Lu-DOTA in patients with high-risk neuroblastoma and other GD2+ solid tumors ” provides an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback